The cell cycle or cell-division cycle is the series of events that take place in a cell leading to its division and duplication of its DNA (DNA replication) to produce two daughter cells. It makes Cell growth. (http://en.wikipedia.org/wiki/Cell_cycle)
G1 (presynthetic growth) -> S (DNA synthesis) -> G2 (premitotic growth) -> M (mitotic)
- G0 (quiescent/senescent)
- Mitotic phase (Mitosis)
Each stage requires completion of the previous step, as well as activation of necessary factors; nonfidelity of DNA replication, or cofactor deficiency result in arrest at the various transition points.
The cell cyle is regulated by activators and inhibitors.
CDKs acquire the ability to phosphorylate protein substrates (i.e., kinase activity) by forming compexes with the relevant cyclins.
Transiently increased synthesis of a particular cyclin leads to increased kinase activity of the appropriate CDK binding partner; as the CDK completes its round of phosphorylation, the associated cyclin is degraded and the CDK activity abates.
Thus, as cyclin levels rise and fall, the activity of associated CDKs likewise wax and wane.
More than 15 cyclins have been identified; cyclins D, E, A, and B appear sequentially during the cell cycle and bind to one or more CDKs.
Table of Contents
Incoming Links #
Related Articles (Article 0) #
Related Medical Scholarly Articles (MedicalScholarlyArticle 1) #
- Biomarkers in triple negative breast cancer: A review
- Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers
- Covalent modifications of histones during development and disease pathogenesis
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype
- Patterns of somatic mutation in human cancer genomes
Related Books (Book 2) #
Related Drugs (Drug 3) #
Suggested Pages #
- 0.144 Haploview
- 0.127 Induced pluripotent stem cell
- 0.104 Polycomb-group proteins
- 0.069 Triple-negative breast cancer
- 0.061 Polycomb regulates mesoderm cell fate-specification in embryonic stem cells through activation and repression mechanisms
- 0.059 Pancreatic cancer
- 0.049 MEL-18 loss mediates estrogen receptor–α downregulation and hormone independence
- 0.030 Receptor tyrosine kinase
- 0.030 CDKN2A
- 0.029 PDCD5
- More suggestions...